Thiopurines in the Management of Crohn’s Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity—A Retrospective Study

Table 1

Baseline characteristics of all patients before and after exclusion due to missing HBI.

	Safety analysis			Efficacy analysis
	Full dose ()	Low dose ()	value	Full dose ()	Low dose ()	value
Age, median (Q1, Q3)	33 (24, 44)	37 (27, 54)	0.130	28 (23, 41)	36 (27, 47)	0.0463
Gender, male	32 (38%)	25 (51%)	0.149	26 (43%)	12 (43%)	1.000
TPMT, median (Q1, Q3)	61 (54, 69)	58 (48, 64)	0.013	62 (55, 69)	53 (44, 61)	0.0002
Disease duration, median (Q1, Q3) years	2 (1, 12)	7 (1, 18)	0.121	2 (0, 9)	9 (1, 18.5)	0.0124
Smoking	30 () (37.5%)	11 () (25%)	0.169	19 () (33%)	4 () (15%)	0.116
Disease location			0.589			0.788
L1	34 (40%)	24 (49%)		25 (41%)	14 (50%)
L2	15 (18%)	8 (16%)		11 (18%)	4 (14%)
L3	36 (42%)	17 (35%)		25 (41%)	10 (36%)
Perianal disease	8 (9%)	9 (18%)	0.178	3 (5%)	7 (25%)	0.0096
Disease behaviour			0.072			0.564
B1	57 (67%)	23 (47%)		42 (69%)	16 (57%)
B2	14 (16.5%)	12 (24%)		9 (15%)	6 (21.5%)
B3	14 (16.5%)	14 (29%)		10 (16%)	6 (21.5%)
Steroid therapy	54 (64%)	31 (63%)	1.000	36 (59%)	17 (61%)	1.000
Systemic steroids	26 (31%)	16 (33%)	0.848	17 (28%)	7 (25%)	1.000
Prior surgery	24 (28%)	14 (29%)	1.000	16 (26%)	6 (21%)	0.793
HBI, median (Q1, Q3)	4 ()	4 ()	0.364	4 (3, 5)	4 (3, 6.5)	0.368
CRP, median	6.3 ()	6.6 ()	0.928	6.7 ()	6.5 ()	0.488